CN102015708B - 作为akt蛋白激酶抑制剂的嘧啶基环戊烷 - Google Patents
作为akt蛋白激酶抑制剂的嘧啶基环戊烷 Download PDFInfo
- Publication number
- CN102015708B CN102015708B CN200980108322.5A CN200980108322A CN102015708B CN 102015708 B CN102015708 B CN 102015708B CN 200980108322 A CN200980108322 A CN 200980108322A CN 102015708 B CN102015708 B CN 102015708B
- Authority
- CN
- China
- Prior art keywords
- methyl
- dihydro
- indoline
- pyrimidin
- spiro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 *C1c2c(N(CC34*N(*)*3)c3c4cccc3)ncnc2C(*)(*)C1 Chemical compound *C1c2c(N(CC34*N(*)*3)c3c4cccc3)ncnc2C(*)(*)C1 0.000 description 17
- XCAOJWNGQLIGJK-UHFFFAOYSA-N CC(C)(C)OC(NCc(c1c(cc2)NCC11CCN(C)CC1)c2Cl)=O Chemical compound CC(C)(C)OC(NCc(c1c(cc2)NCC11CCN(C)CC1)c2Cl)=O XCAOJWNGQLIGJK-UHFFFAOYSA-N 0.000 description 1
- VOGHVPSNXQFTID-UHFFFAOYSA-N CC(C)(C)OC(NCc1cccc(N(C2)C(OC(C)(C)C)=O)c1C21CCN(C)CC1)=O Chemical compound CC(C)(C)OC(NCc1cccc(N(C2)C(OC(C)(C)C)=O)c1C21CCN(C)CC1)=O VOGHVPSNXQFTID-UHFFFAOYSA-N 0.000 description 1
- QMVVUGDBQVKFCW-UHFFFAOYSA-N CC(C)(C)OC(NCc1cccc(NC2)c1C21CCN(C)CC1)=O Chemical compound CC(C)(C)OC(NCc1cccc(NC2)c1C21CCN(C)CC1)=O QMVVUGDBQVKFCW-UHFFFAOYSA-N 0.000 description 1
- CHZWGZJRDOATOW-HSZRJFAPSA-N CC(C)NCc(c(CCCCCCCC1)c(cc2)N1c1ncnc([C@@H](C3)O)c1C3=C)c2Cl Chemical compound CC(C)NCc(c(CCCCCCCC1)c(cc2)N1c1ncnc([C@@H](C3)O)c1C3=C)c2Cl CHZWGZJRDOATOW-HSZRJFAPSA-N 0.000 description 1
- OWPDZYLYPSEWTE-YLEKAMJDSA-N CC(C)NCc1c([C@@]2(CNCC2)CN2c3c([C@H](C)C[C@H]4O)c4ncn3)c2ccc1 Chemical compound CC(C)NCc1c([C@@]2(CNCC2)CN2c3c([C@H](C)C[C@H]4O)c4ncn3)c2ccc1 OWPDZYLYPSEWTE-YLEKAMJDSA-N 0.000 description 1
- MVOSNPUNXINWAD-UHFFFAOYSA-N CC(c(cc1)ccc1Cl)O Chemical compound CC(c(cc1)ccc1Cl)O MVOSNPUNXINWAD-UHFFFAOYSA-N 0.000 description 1
- PSDSORRYQPTKSV-UHFFFAOYSA-N CC(c(cc1)ccc1F)O Chemical compound CC(c(cc1)ccc1F)O PSDSORRYQPTKSV-UHFFFAOYSA-N 0.000 description 1
- CTWKDSQETUYEAI-UHFFFAOYSA-N CCNCC(NC)=O Chemical compound CCNCC(NC)=O CTWKDSQETUYEAI-UHFFFAOYSA-N 0.000 description 1
- CXGFWBPQQXZELI-UHFFFAOYSA-N CCNc1ncccc1 Chemical compound CCNc1ncccc1 CXGFWBPQQXZELI-UHFFFAOYSA-N 0.000 description 1
- PAMIQIKDUOTOBW-UHFFFAOYSA-N CN1CCCCC1 Chemical compound CN1CCCCC1 PAMIQIKDUOTOBW-UHFFFAOYSA-N 0.000 description 1
- KTTOSBNNSXPZDO-RXMQYKEDSA-N C[C@H](C1)c2c(C)ncnc2C1(F)F Chemical compound C[C@H](C1)c2c(C)ncnc2C1(F)F KTTOSBNNSXPZDO-RXMQYKEDSA-N 0.000 description 1
- KGZPZVFJSRMGSW-QRIPLOBPSA-N C[C@H](C1)c2c(N(CC34CCN(C)CC3)c(cc3)c4c(CNC(OC(C)(C)C)=O)c3Cl)ncnc2C1O Chemical compound C[C@H](C1)c2c(N(CC34CCN(C)CC3)c(cc3)c4c(CNC(OC(C)(C)C)=O)c3Cl)ncnc2C1O KGZPZVFJSRMGSW-QRIPLOBPSA-N 0.000 description 1
- IUIOSRAXWYMSPD-QVKFZJNVSA-N C[C@H](CC1)c2c1ncnc2N(C1)c2ccc(C)cc2[C@]11CNCCC1 Chemical compound C[C@H](CC1)c2c1ncnc2N(C1)c2ccc(C)cc2[C@]11CNCCC1 IUIOSRAXWYMSPD-QVKFZJNVSA-N 0.000 description 1
- JVOVSFLQQWIRFB-RXIOXGHVSA-N C[C@H](CC1)c2c1ncnc2N(C[C@@](CCC1)(CN1[C@@H](CCN)c(cc1)ccc1Cl)c1c2)c1ccc2F Chemical compound C[C@H](CC1)c2c1ncnc2N(C[C@@](CCC1)(CN1[C@@H](CCN)c(cc1)ccc1Cl)c1c2)c1ccc2F JVOVSFLQQWIRFB-RXIOXGHVSA-N 0.000 description 1
- NXKBNSHFMCJEOF-XPHRQAEKSA-N C[C@H](CC1)c2c1ncnc2N(C[C@@](CCC1)(CN1[C@H](CCN)c(cc1)ccc1Cl)c1c2)c1ccc2[IH]C Chemical compound C[C@H](CC1)c2c1ncnc2N(C[C@@](CCC1)(CN1[C@H](CCN)c(cc1)ccc1Cl)c1c2)c1ccc2[IH]C NXKBNSHFMCJEOF-XPHRQAEKSA-N 0.000 description 1
- GVRMLHVGEWEIDI-MRXNPFEDSA-N C[C@H]1c2c(N(CC34CCN(CCCN)CC3)c(cc3)c4cc3Cl)ncnc2CC1 Chemical compound C[C@H]1c2c(N(CC34CCN(CCCN)CC3)c(cc3)c4cc3Cl)ncnc2CC1 GVRMLHVGEWEIDI-MRXNPFEDSA-N 0.000 description 1
- KWUNASPZIIYLQK-QGZVFWFLSA-N C[C@H]1c2c(N(CC34CCNCC3)c(cc3)c4c(CNC4CCCC4)c3Cl)ncnc2CC1 Chemical compound C[C@H]1c2c(N(CC34CCNCC3)c(cc3)c4c(CNC4CCCC4)c3Cl)ncnc2CC1 KWUNASPZIIYLQK-QGZVFWFLSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Physical Education & Sports Medicine (AREA)
- Endocrinology (AREA)
- Communicable Diseases (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Transplantation (AREA)
- Obesity (AREA)
- Virology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Psychology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Emergency Medicine (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US2012508P | 2008-01-09 | 2008-01-09 | |
| US61/020,125 | 2008-01-09 | ||
| PCT/US2009/030603 WO2009089454A1 (en) | 2008-01-09 | 2009-01-09 | Pyrimidyl cyclopentanes as akt protein kinase inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102015708A CN102015708A (zh) | 2011-04-13 |
| CN102015708B true CN102015708B (zh) | 2014-03-26 |
Family
ID=40436385
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN200980108322.5A Active CN102015708B (zh) | 2008-01-09 | 2009-01-09 | 作为akt蛋白激酶抑制剂的嘧啶基环戊烷 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US8324221B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2240483B8 (cg-RX-API-DMAC7.html) |
| JP (1) | JP5512545B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN102015708B (cg-RX-API-DMAC7.html) |
| AR (1) | AR070136A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2714888C (cg-RX-API-DMAC7.html) |
| CL (1) | CL2009000035A1 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2403284T3 (cg-RX-API-DMAC7.html) |
| PE (1) | PE20091315A1 (cg-RX-API-DMAC7.html) |
| TW (1) | TW200940542A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2009089454A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CL2009000035A1 (es) | 2008-01-09 | 2009-11-27 | Array Biopharma Inc | Compuestos derivados 3-espiro-heterociclo-1il-5h-ciclopentan[d]pirimidin-indol, util para inhibir la actividad de akt quinasa; composicion farmaceutica que comprende dichos compuestos; y uso en el tratamiento de enfermedades tal como cancer, fibrosis quistica, diabetes, enfermedad de alzheimer, entre otras. |
| US20100048914A1 (en) | 2008-03-14 | 2010-02-25 | Angela Brodie | Novel C-17-Heteroaryl Steroidal Cyp17 Inhibitors/Antiandrogens, In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity |
| SI2285808T1 (sl) | 2008-04-29 | 2014-03-31 | Novartis Ag | Spiro-indolni derivati za zdravljenje parazitskih bolezni |
| BRPI1008745A2 (pt) | 2009-02-05 | 2019-09-17 | Tokai Pharmaceuticals Inc | pró-fármacos de inibidores esteroidais de cyp17/antiandrogênios |
| TWI466885B (zh) | 2009-07-31 | 2015-01-01 | Japan Tobacco Inc | 含氮螺環化合物及其醫藥用途 |
| WO2013057944A1 (ja) | 2011-10-19 | 2013-04-25 | 興和株式会社 | 新規なスピロインドリン化合物、及びそれを含有する医薬 |
| LT2841075T (lt) | 2012-04-26 | 2020-07-10 | The General Hospital Corporation | Seborėjinės keratozės gydymui ir profilaktikai skirti agentai ir metodai |
| SG11201507093WA (en) | 2013-03-14 | 2015-10-29 | Univ Maryland Baltimore Office Of Technology Transfer | Androgen receptor down-regulating agents and uses thereof |
| WO2014186663A2 (en) * | 2013-05-17 | 2014-11-20 | The General Hospital Corporation | Methods for detecting and treating variants of seborrheic keratoses |
| CA2920317A1 (en) | 2013-08-12 | 2015-02-19 | Tokai Pharmaceuticals, Inc. | Biomarkers for treatment of neoplastic disorders using androgen-targeted therapies |
| US10183934B2 (en) | 2015-02-02 | 2019-01-22 | Forma Therapeutics, Inc. | Bicyclic [4,6,0] hydroxamic acids as HDAC inhibitors |
| SG11201706146UA (en) | 2015-02-02 | 2017-08-30 | Forma Therapeutics Inc | 3-alkyl-4-amido-bicyclic [4,5,0] hydroxamic acids as hdac inhibitors |
| EA201792028A1 (ru) | 2015-03-13 | 2018-04-30 | Форма Терапьютикс, Инк. | Альфа-цинамидные соединения и композиции как ингибиторы hdac8 |
| WO2017218950A1 (en) | 2016-06-17 | 2017-12-21 | Forma Therapeutics, Inc. | 2-spiro-5- and 6-hydroxamic acid indanes as hdac inhibitors |
| EP3703675A4 (en) | 2017-10-30 | 2021-06-16 | Neuropore Therapies, Inc. | SUBSTITUTED PHENYLSULFONYLPHÉNYLTRIAZOLETHIONES AND ASSOCIATED USES |
| TWI830733B (zh) * | 2018-05-11 | 2024-02-01 | 中國大陸商迪哲（江蘇）醫藥有限公司 | 環戊烷化合物 |
| WO2021118924A2 (en) | 2019-12-12 | 2021-06-17 | Ting Therapeutics Llc | Compositions and methods for the prevention and treatment of hearing loss |
| WO2022109360A1 (en) | 2020-11-23 | 2022-05-27 | Enanta Pharmaceuticals, Inc. | Novel spiropyrrolidine derived antiviral agents |
| WO2022235605A1 (en) | 2021-05-04 | 2022-11-10 | Enanta Pharmaceuticals, Inc. | Novel macrocyclic antiviral agents |
| US12398147B2 (en) | 2021-05-11 | 2025-08-26 | Enanta Pharmaceuticals, Inc. | Macrocyclic spiropyrrolidine derived antiviral agents |
| US12479854B2 (en) | 2021-07-29 | 2025-11-25 | Enanta Pharmaceuticals, Inc. | Spiropyrrolidine derived antiviral agents |
| WO2023086352A1 (en) | 2021-11-12 | 2023-05-19 | Enanta Pharmaceuticals, Inc. | Novel spiropyrrolidine derived antiviral agents |
| WO2023086400A1 (en) | 2021-11-12 | 2023-05-19 | Enanta Pharmaceuticals, Inc. | Novel spiropyrrolidine derived antiviral agents |
| US11858945B2 (en) | 2021-11-12 | 2024-01-02 | Enanta Pharmaceuticals, Inc. | Alkyne-containing antiviral agents |
| US20230159546A1 (en) * | 2021-11-18 | 2023-05-25 | Enanta Pharmaceuticals, Inc. | Novel spiropyrrolidine derived antiviral agents |
| US12145941B2 (en) | 2021-12-08 | 2024-11-19 | Enanta Pharmaceuticals, Inc. | Heterocyclic antiviral agents |
| US11993600B2 (en) | 2021-12-08 | 2024-05-28 | Enanta Pharmaceuticals, Inc. | Saturated spirocyclics as antiviral agents |
| US12145942B2 (en) | 2022-04-05 | 2024-11-19 | Enanta Pharmaceuticals, Inc. | Spiropyrrolidine derived antiviral agents |
| CN114751852B (zh) * | 2022-05-23 | 2023-09-15 | 山西库邦生物医药科技有限公司 | 一种西咯多辛关键中间体的制备方法 |
| IL317105A (en) * | 2022-06-03 | 2025-01-01 | Domain Therapeutics | New PAR-2 inhibitors |
| CN116903625B (zh) * | 2023-02-16 | 2025-09-23 | 广州安岩仁医药科技有限公司 | 一种egfr抑制剂中间体及其合成方法与应用 |
| CN117700429A (zh) * | 2023-12-21 | 2024-03-15 | 广州白云科技股份有限公司 | 聚氨酯扩链剂、聚氨酯预聚体、力致变色聚氨酯胶及其制备方法 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004509115A (ja) * | 2000-09-15 | 2004-03-25 | バーテックス ファーマシューティカルズ インコーポレイテッド | プロテインキナーゼインヒビターとして有用なピラゾール化合物 |
| JP2007512364A (ja) | 2003-11-21 | 2007-05-17 | アレイ バイオファーマ、インコーポレイテッド | Ａｋｔプロテインキナーゼインヒビター |
| WO2005113762A1 (en) | 2004-05-18 | 2005-12-01 | Pfizer Products Inc. | CRYSTAL STRUCTURE OF PROTEIN KINASE B-α (AKT-1) AND USES THEREOF |
| JP2008531542A (ja) * | 2005-02-24 | 2008-08-14 | ファイザー・プロダクツ・インク | 抗癌剤として有用な二環式複素芳香族誘導体 |
| US7495007B2 (en) | 2006-03-13 | 2009-02-24 | Hoffmann-La Roche Inc. | Spiroindolinone derivatives |
| UA95641C2 (xx) | 2006-07-06 | 2011-08-25 | Эррей Биофарма Инк. | Гідроксильовані піримідильні циклопентани як інгібітори акт протеїнкінази$гидроксилированные пиримидильные циклопентаны как ингибиторы акт протеинкиназы |
| SI2049500T1 (sl) | 2006-07-06 | 2012-01-31 | Array Biopharma Inc | Ciklopenta (d) pirimidini kot AKT protein kinazni inhibitorji |
| US8063050B2 (en) | 2006-07-06 | 2011-11-22 | Array Biopharma Inc. | Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors |
| US20080051419A1 (en) | 2006-07-26 | 2008-02-28 | Pfizer Inc. | Amine derivatives useful as anticancer agents |
| UY31162A1 (es) | 2007-06-20 | 2008-11-28 | Glaxo Group Ltd | Espiroindolinas como moduladores de receptores de quimioquinas |
| KR20150089099A (ko) | 2007-07-05 | 2015-08-04 | 어레이 바이오파마 인크. | Ａｋｔ 단백질 키나제 억제제로서의 피리미딜 시클로펜탄 |
| CL2009000035A1 (es) | 2008-01-09 | 2009-11-27 | Array Biopharma Inc | Compuestos derivados 3-espiro-heterociclo-1il-5h-ciclopentan[d]pirimidin-indol, util para inhibir la actividad de akt quinasa; composicion farmaceutica que comprende dichos compuestos; y uso en el tratamiento de enfermedades tal como cancer, fibrosis quistica, diabetes, enfermedad de alzheimer, entre otras. |
-
2009
- 2009-01-09 CL CL2009000035A patent/CL2009000035A1/es unknown
- 2009-01-09 AR ARP090100067A patent/AR070136A1/es not_active Application Discontinuation
- 2009-01-09 ES ES09700747T patent/ES2403284T3/es active Active
- 2009-01-09 CA CA2714888A patent/CA2714888C/en not_active Expired - Fee Related
- 2009-01-09 PE PE2009000021A patent/PE20091315A1/es not_active Application Discontinuation
- 2009-01-09 TW TW098100759A patent/TW200940542A/zh unknown
- 2009-01-09 JP JP2010542374A patent/JP5512545B2/ja active Active
- 2009-01-09 CN CN200980108322.5A patent/CN102015708B/zh active Active
- 2009-01-09 US US12/812,384 patent/US8324221B2/en active Active
- 2009-01-09 EP EP09700747A patent/EP2240483B8/en active Active
- 2009-01-09 WO PCT/US2009/030603 patent/WO2009089454A1/en not_active Ceased
-
2012
- 2012-11-14 US US13/676,963 patent/US9346805B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| PE20091315A1 (es) | 2009-09-21 |
| EP2240483B1 (en) | 2013-02-27 |
| HK1149270A1 (en) | 2011-09-30 |
| JP5512545B2 (ja) | 2014-06-04 |
| EP2240483B8 (en) | 2013-04-03 |
| JP2011509307A (ja) | 2011-03-24 |
| CL2009000035A1 (es) | 2009-11-27 |
| CN102015708A (zh) | 2011-04-13 |
| US20110053959A1 (en) | 2011-03-03 |
| US20130072500A1 (en) | 2013-03-21 |
| AR070136A1 (es) | 2010-03-17 |
| WO2009089454A1 (en) | 2009-07-16 |
| US8324221B2 (en) | 2012-12-04 |
| CA2714888A1 (en) | 2009-07-16 |
| EP2240483A1 (en) | 2010-10-20 |
| TW200940542A (en) | 2009-10-01 |
| CA2714888C (en) | 2017-03-14 |
| US9346805B2 (en) | 2016-05-24 |
| ES2403284T3 (es) | 2013-05-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102015708B (zh) | 作为akt蛋白激酶抑制剂的嘧啶基环戊烷 | |
| CN101631778B (zh) | 作为akt蛋白激酶抑制剂的环戊二烯并[d]嘧啶 | |
| CN104884458B (zh) | 作为蛋白质激酶抑制剂的稠合杂环化合物 | |
| CN103415520B (zh) | 吡咯并六元杂芳环类衍生物、其制备方法及其在医药上的应用 | |
| CN101801955B (zh) | 作为akt蛋白激酶抑制剂的嘧啶基环戊烷 | |
| CN101578273A (zh) | 作为akt蛋白激酶抑制剂的羟基化和甲氧基化的环戊二烯并[d]嘧啶 | |
| WO2013078254A1 (en) | Bicyclic heteroaryl derivatives as kinase inhibitors | |
| KR20130086520A (ko) | 스피로시클릭 화합물 및 이들의 치료제 및 진단 프로브로서 용도 | |
| KR20180031823A (ko) | 피리다지논, 그의 제조 방법 및 사용 방법 | |
| CN102906095A (zh) | 作为syk和jak抑制剂的吡咯并吡嗪衍生物 | |
| CN101516891A (zh) | 作为akt蛋白激酶抑制剂的二氢噻吩并嘧啶 | |
| HK1149270B (en) | Pyrimidyl cyclopentanes as akt protein kinase inhibitors | |
| TWI602818B (zh) | 稠合雜環化合物作爲蛋白激酶抑制劑 | |
| HK1126758B (en) | Cyclopenta [d] pyrimidines as akt protein kinase inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |